Close this search box.

by Amanda Conschafter, blog editor

Five years after the federal government approved an abbreviated regulatory pathway for biosimilars, physicians and patients still lack clarity on a number of core issues. So explains a new policy brief from the Institute for Patient Access, which notes that regulators must resolve these issues—particularly if they hope to instill confidence and ensure widespread adoption of biosimilars.

In “Unresolved Policy Issues Impact Patient Access to Biosimilars,” authors David Charles, MD, and Mary Ann Chapman, PhD, cite four central policy issues that require further action by regulators. These include:

For more information, read “Unresolved Policy Issues Impact Patient Access to Biosimilars,” or visit AfPA’s educational video library.

Leave a Reply

Your email address will not be published. Required fields are marked *